EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Sold by Oracle Investment Management Inc.

Oracle Investment Management Inc. decreased its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 91.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,500 shares of the company's stock after selling 350,000 shares during the quarter. EyePoint Pharmaceuticals accounts for 0.1% of Oracle Investment Management Inc.'s portfolio, making the stock its 15th largest position. Oracle Investment Management Inc.'s holdings in EyePoint Pharmaceuticals were worth $242,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. RA Capital Management L.P. bought a new stake in EyePoint Pharmaceuticals in the fourth quarter valued at approximately $23,705,000. TCG Crossover Management LLC raised its holdings in EyePoint Pharmaceuticals by 287.3% during the 4th quarter. TCG Crossover Management LLC now owns 3,572,335 shares of the company's stock valued at $26,614,000 after buying an additional 2,650,000 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its position in EyePoint Pharmaceuticals by 51.7% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,750,000 shares of the company's stock valued at $42,838,000 after buying an additional 1,958,580 shares during the period. Federated Hermes Inc. grew its holdings in EyePoint Pharmaceuticals by 92.7% in the 4th quarter. Federated Hermes Inc. now owns 3,707,445 shares of the company's stock worth $27,620,000 after acquiring an additional 1,783,765 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of EyePoint Pharmaceuticals by 24.8% in the fourth quarter. Vanguard Group Inc. now owns 3,803,227 shares of the company's stock valued at $28,334,000 after acquiring an additional 755,045 shares during the period. Hedge funds and other institutional investors own 99.41% of the company's stock.

EyePoint Pharmaceuticals Stock Performance

EYPT stock traded down $0.51 during trading on Tuesday, reaching $6.35. The company had a trading volume of 364,774 shares, compared to its average volume of 875,881. EyePoint Pharmaceuticals, Inc. has a twelve month low of $3.91 and a twelve month high of $14.00. The company has a market cap of $436.95 million, a price-to-earnings ratio of -3.17 and a beta of 1.39. The firm has a 50-day simple moving average of $6.02 and a 200-day simple moving average of $7.60.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last issued its earnings results on Wednesday, March 5th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.10). The firm had revenue of $11.60 million during the quarter, compared to analysts' expectations of $11.02 million. EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. Sell-side analysts expect that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. HC Wainwright reissued a "buy" rating and set a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research note on Thursday, March 6th. Citigroup began coverage on EyePoint Pharmaceuticals in a research note on Tuesday, January 7th. They set a "buy" rating and a $33.00 price objective for the company. Chardan Capital restated a "buy" rating and issued a $33.00 price target on shares of EyePoint Pharmaceuticals in a research note on Thursday, March 6th. Finally, StockNews.com upgraded EyePoint Pharmaceuticals to a "sell" rating in a research report on Friday, March 14th. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $26.63.

EyePoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.